CD22 and acute lymphoblastic leukemia: While this adds to treatment options in the salvage settings for pediatric B-ALL, InO might not be an efficacious agent in KMT2A-r B-ALL, given that the lower CD22 expression in these patients leads to poor InO binding and activity.45,46